161 related articles for article (PubMed ID: 26729302)
1. Cinacalcet versus standard treatment for chronic kidney disease: a protocol for a systematic review and meta-analysis.
Sekercioglu N; Busse JW; Mustafa RA; Guyatt GH; Thabane L
Syst Rev; 2016 Jan; 5():2. PubMed ID: 26729302
[TBL] [Abstract][Full Text] [Related]
2. Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis.
Sekercioglu N; Busse JW; Sekercioglu MF; Agarwal A; Shaikh S; Lopes LC; Mustafa RA; Guyatt GH; Thabane L
Ren Fail; 2016 Jul; 38(6):857-74. PubMed ID: 27137817
[TBL] [Abstract][Full Text] [Related]
3. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.
Sekercioglu N; Thabane L; Díaz Martínez JP; Nesrallah G; Longo CJ; Busse JW; Akhtar-Danesh N; Agarwal A; Al-Khalifah R; Iorio A; Guyatt GH
PLoS One; 2016; 11(6):e0156891. PubMed ID: 27276077
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).
Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755
[TBL] [Abstract][Full Text] [Related]
6. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
7. Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis.
Palmer SC; Teixeira-Pinto A; Saglimbene V; Craig JC; Macaskill P; Tonelli M; de Berardis G; Ruospo M; Strippoli GF
Am J Kidney Dis; 2015 Dec; 66(6):962-71. PubMed ID: 26003472
[TBL] [Abstract][Full Text] [Related]
8. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials.
Palmer SC; Nistor I; Craig JC; Pellegrini F; Messa P; Tonelli M; Covic A; Strippoli GF
PLoS Med; 2013; 10(4):e1001436. PubMed ID: 23637579
[TBL] [Abstract][Full Text] [Related]
9. Chronic hemodialysis patients without marked elevation of intact parathyroid hormone are also good candidates for early intervention with cinacalcet.
Nishida H; Masakane I; Kudo K; Ito M; Tanida H; Koshika M; Nishida W; Tomita Y
Ther Apher Dial; 2013 Jun; 17(3):325-31. PubMed ID: 23735149
[TBL] [Abstract][Full Text] [Related]
10. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
11. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
Bover J; Ureña-Torres P; Lloret MJ; Ruiz C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
Expert Opin Pharmacother; 2016 Jul; 17(10):1363-73. PubMed ID: 27156578
[TBL] [Abstract][Full Text] [Related]
12. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of cinacalcet in the treatment of CKD-MBD].
Koiwa F; Maruta Y
Clin Calcium; 2010 Jul; 20(7):1089-95. PubMed ID: 20585188
[TBL] [Abstract][Full Text] [Related]
13. Safety of cinacalcet in children and adolescents with chronic kidney disease-mineral bone disorder: systematic review and proportional meta-analysis of case series.
Zamoner SMS; Takase HM; Riyuzo MC; Caramori JCT; de Andrade LGM
Int Urol Nephrol; 2024 May; 56(5):1669-1676. PubMed ID: 37964112
[TBL] [Abstract][Full Text] [Related]
14. Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D.
Yusuf AA; Howell BL; Powers CA; St Peter WL
Am J Kidney Dis; 2014 Nov; 64(5):770-80. PubMed ID: 24833203
[TBL] [Abstract][Full Text] [Related]
15. Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.
Wesseling-Perry K; Salusky IB
Pediatr Nephrol; 2013 Apr; 28(4):617-25. PubMed ID: 23381010
[TBL] [Abstract][Full Text] [Related]
16. Cinacalcet for Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: A Meta-Analysis of Randomized Controlled Trials.
Greeviroj P; Kitrungphaiboon T; Katavetin P; Praditpornsilpa K; Eiam-Ong S; Jaber BL; Susantitaphong P
Nephron; 2018; 139(3):197-210. PubMed ID: 29514156
[TBL] [Abstract][Full Text] [Related]
17. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.
Ritter C; Miller B; Coyne DW; Gupta D; Zheng S; Brown AJ; Slatopolsky E
Kidney Int; 2017 Nov; 92(5):1217-1222. PubMed ID: 28750928
[TBL] [Abstract][Full Text] [Related]
18. The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ye Z; Silverberg SJ; Sreekanta A; Tong K; Wang Y; Chang Y; Zhang M; Guyatt G; Tangamornsuksun W; Zhang Y; Manja V; Bakaa L; Couban RJ; Brandi ML; Clarke B; Khan AA; Mannstadt M; Bilezikian JP
J Bone Miner Res; 2022 Nov; 37(11):2351-2372. PubMed ID: 36053960
[TBL] [Abstract][Full Text] [Related]
19. Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study.
Tanaka M; Yoshida K; Fukuma S; Ito K; Matsushita K; Fukagawa M; Fukuhara S; Akizawa T
PLoS One; 2016; 11(10):e0164865. PubMed ID: 27764168
[TBL] [Abstract][Full Text] [Related]
20. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective.
Garside R; Pitt M; Anderson R; Mealing S; D'Souza R; Stein K
Nephrol Dial Transplant; 2007 May; 22(5):1428-36. PubMed ID: 17308322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
